Provectus Biopharmaceuticals, Inc. is a development-stage biopharmaceutical company. The Company is engaged in developing pharmaceuticals for oncology and dermatology indications. The Company is focused on developing its prescription drug candidates, PV-10 and PH-10. It is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer and breast cancer. It is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions, such as psoriasis and atopic dermatitis, a type of eczema. In addition to clinical trials, patients enrolled in the expanded access or compassionate use program for PV-10 are also receiving PV-10 treatments for cutaneous and subcutaneous cancer indications. The Company also focuses on over-the-counter (OTC) products and various other non-core technologies. PV-10 is a sterile injectable form of rose bengal disodium (Rose Bengal), for direct injection into tumors.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Manufacturers - Major
- Sub-Industry: N/A
- Symbol: NYSEMKT:PVCT
- CUSIP: N/A
- Web: www.provectusbio.com/
- 50 Day Moving Avg: $0.04
- 200 Day Moving Avg: $0.03
- Trailing P/E Ratio: N/A
- P/E Growth: 0.0000
- Return on Equity: -1,385.91%
- Return on Assets: -347.90%
Frequently Asked Questions for Provectus Biopharmaceuticals (NYSEMKT:PVCT)
What is Provectus Biopharmaceuticals' stock symbol?
Provectus Biopharmaceuticals trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "PVCT."
Who are some of Provectus Biopharmaceuticals' key competitors?
Some companies that are related to Provectus Biopharmaceuticals include Cogentix Medical (CGNT), CytoDyn (CYDY), Affimed N.V. (AFMD), Vericel Corporation (VCEL), Aralez Pharmaceuticals (ARLZ), Neovasc (NVCN), Alimera Sciences (ALIM), CTI BioPharma Corp. (CTIC), Zafgen (ZFGN), Proteostasis Therapeutics (PTI), Protalix Biotherapeutics (PLX), Ophthotech Corporation (OPHT), Vermillion (VRML), CytRx Corporation (CYTR), iRadimed Corporation (IRMD), ArQule (ARQL), GTx (GTXI) and Lipocine (LPCN).
Who are Provectus Biopharmaceuticals' key executives?
Provectus Biopharmaceuticals' management team includes the folowing people:
- Dominic Rodrigues, Chairman of the Board
- Timothy C. Scott Ph.D., President
- John R. Glass CPA, Interim Chief Financial Officer
- Eric A. Wachter Ph.D., Chief Technology Officer, Director
- Bruce Horowitz, Director
- Jan E Koe, Independent Director
How do I buy Provectus Biopharmaceuticals stock?
Shares of Provectus Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Provectus Biopharmaceuticals' stock price today?
MarketBeat Community Rating for Provectus Biopharmaceuticals (NYSEMKT PVCT)MarketBeat's community ratings are surveys of what our community members think about Provectus Biopharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Provectus Biopharmaceuticals stock can currently be purchased for approximately $0.83.
Consensus Ratings for Provectus Biopharmaceuticals (NYSEMKT:PVCT) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Provectus Biopharmaceuticals (NYSEMKT:PVCT)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Provectus Biopharmaceuticals (NYSEMKT:PVCT)Earnings History by Quarter for Provectus Biopharmaceuticals (NYSEMKT PVCT)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Provectus Biopharmaceuticals (NYSEMKT:PVCT)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Provectus Biopharmaceuticals (NYSEMKT:PVCT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Provectus Biopharmaceuticals (NYSEMKT:PVCT)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Provectus Biopharmaceuticals (NYSEMKT:PVCT)
Latest Headlines for Provectus Biopharmaceuticals (NYSEMKT:PVCT)
|Provectus Biopharmaceuticals Reestablishes Strategic Advisory Board|
finance.yahoo.com - April 20 at 7:29 PM
|Provectus Biopharmaceuticals Closes Definitive Financing With PRH Group|
finance.yahoo.com - April 7 at 12:08 PM
|PROVECTUS BIOPHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report|
biz.yahoo.com - March 31 at 7:34 PM
|PROVECTUS BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disc|
biz.yahoo.com - March 23 at 7:53 PM
|Provectus Biopharmaceuticals Announces Terms Of Definitive Financing Commitment|
finance.yahoo.com - March 23 at 7:53 PM
|Provectus Biopharmaceuticals, Inc. Announces Extension Of Rights Offering Due To Receipt Of Unsolicited Investment Proposals To Invest In Provectus|
us.rd.yahoo.com - March 6 at 8:43 AM
|Provectus Biopharmaceuticals Provides Information On Rights Offering Deadline|
us.rd.yahoo.com - February 24 at 8:36 PM
|PROVECTUS BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits|
biz.yahoo.com - February 15 at 12:01 AM
|Provectus Biopharmaceuticals, Inc. Announces Extension of Rights Offering - PR Newswire (press release)|
www.prnewswire.com - February 12 at 8:28 AM
|Provectus Biopharmaceuticals, Inc. Announces Extension of Rights Offering|
finance.yahoo.com - February 10 at 9:47 PM
|PROVECTUS BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modificat|
biz.yahoo.com - February 8 at 9:37 PM
|How These Drug Makers Stocks are Faring? -- Provectus Biopharma, TherapeuticsMD, Novartis, and Tonix Pharma|
www.bizjournals.com - February 3 at 8:20 PM
|Provectus commences rights offering to stockholders - Seeking Alpha|
seekingalpha.com - February 1 at 10:11 PM
|Provectus Biopharmaceuticals, Inc. Announces Commencement Of Rights Offering To Existing Stockholders And Holders Of Certain Warrants|
finance.yahoo.com - January 31 at 9:19 PM
|Provectus Biopharmaceuticals Terminates Peter Culpepper as Interim CEO and COO - Business Wire (press release)|
www.businesswire.com - December 31 at 12:46 AM